Acne News with Dr. Adam Friedman
Straight from the desk of ODAC Medical Director, Dr. Adam Friedman, we share what’s popping in acne (spoiler alert: quite a lot!). According to Dr. Friedman, the innovation drought is over! Watch as he reviews all new topical and oral therapeutics (some of which are completely new active agents) and while at it, shares and debunks important information related to the management of acne vulgaris …
Straight from the desk of ODAC Medical Director, Dr. Adam Friedman, we share what’s popping in acne (spoiler alert: quite a lot!). According to Dr. Friedman, the innovation drought is over! Watch as he reviews all new topical and oral therapeutics (some of which are completely new active agents) and while at it, shares and debunks important information related to the management of acne vulgaris … 
When Matthew Willett, MD, began his dermatology training, he felt he had to choose between dermatology and his family.
“My kids were old enough to tell me that they missed spending time with me, and that made it even harder sometimes,” said Dr. Willett, who is now a staff dermatologist in Rhode Island.
“Sometimes the kids really know how to play up the ‘guilt game,’” said Jackie … 
Treatment of malignancy with anti-programmed cell death 1 (PD-1) immune checkpoint inhibitors can cause mucocutaneous side effects resulting from T cell activation. Due to their recent development, the full side effect profile remains to be fully elucidated, however dermatologic adverse events are most common. The main oral toxicities of these immune checkpoint inhibitors include: xerostomia, dysg … 
I believe one of the most valuable aspects of attending conferences such as ODAC is to “fill in the gaps” in important topics that are often missing in our regular dermatology training. While US dermatology residency programs provide the foundation for providing the highest level of dermatologic care to our patients, they are often lacking in teaching the business side of medicine and practica … 
Atopic dermatitis (AD) is a common skin condition characterized by pruritus and occurs as a result of factors related to impaired skin barrier and immune response, as well as environmental and infectious agents. Patients with poor control on topical therapy are looking for safe and effective systemic treatments. We continue our series, Therapeutic Cheat Sheet, with a closer look at dupilumab, whic …